TITAN PHARMACEUTICALS INC — Director's Dealing 2018

Mar 9, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TITAN PHARMACEUTICALS INC (TTNP)
CIK: 0000910267
Period of Report: 2018-03-07

Reporting Person: Rubin Marc (Director, Executive Chairman)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-03-07	Option to Purchase Common Stock	$0.97	A	170000	Acquired	2028-03-07	Common Stock (170000)	Direct

Footnotes

F1: The options vest as to 25% on the grant date and 25% on each of the three month, six month and nine month anniversaries of the grant date.